Genetic Therapy
"Genetic Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
Descriptor ID |
D015316
|
MeSH Number(s) |
E02.095.301 E05.393.420.301
|
Concept/Terms |
Genetic Therapy- Genetic Therapy
- Genetic Therapies
- Therapies, Genetic
- Therapy, Genetic
- Therapy, DNA
- DNA Therapy
Genetic Therapy, Somatic- Genetic Therapy, Somatic
- Genetic Therapies, Somatic
- Somatic Genetic Therapies
- Somatic Genetic Therapy
- Therapies, Somatic Genetic
- Therapy, Somatic Genetic
Genetic Therapy, Gametic- Genetic Therapy, Gametic
- Gametic Genetic Therapies
- Gametic Genetic Therapy
- Genetic Therapies, Gametic
- Therapies, Gametic Genetic
- Therapy, Gametic Genetic
|
Below are MeSH descriptors whose meaning is more general than "Genetic Therapy".
Below are MeSH descriptors whose meaning is more specific than "Genetic Therapy".
This graph shows the total number of publications written about "Genetic Therapy" by people in UAMS Profiles by year, and whether "Genetic Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2025 | 1 | 0 | 1 | 2024 | 5 | 1 | 6 | 2023 | 1 | 0 | 1 | 2021 | 0 | 1 | 1 | 2020 | 6 | 0 | 6 | 2019 | 0 | 1 | 1 | 2016 | 1 | 1 | 2 | 2015 | 1 | 2 | 3 | 2014 | 1 | 3 | 4 | 2013 | 1 | 0 | 1 | 2012 | 1 | 0 | 1 | 2011 | 1 | 3 | 4 | 2010 | 3 | 3 | 6 | 2009 | 5 | 1 | 6 | 2008 | 5 | 0 | 5 | 2007 | 1 | 0 | 1 | 2006 | 1 | 1 | 2 | 2005 | 2 | 1 | 3 | 2004 | 1 | 1 | 2 | 2002 | 1 | 1 | 2 | 2001 | 0 | 2 | 2 | 1999 | 2 | 0 | 2 | 1998 | 1 | 0 | 1 | 1997 | 1 | 0 | 1 | 1993 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Genetic Therapy" by people in Profiles over the past ten years.
-
Samanta D, Bhatia S, Hunter SE, Rao CK, Xiong K, Karakas C, Reeders PC, Erdemir G, Sattar S, Axeen E, Sandoval Karamian AG, Fine AL, Keator CG, Nolan D, Schreiber JM. Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies. Pediatr Neurol. 2025 Jul; 168:67-81.
-
Kaufman BD, Veerapandiyan A, Soslow JH, Wittlieb-Weber C, Esteso P, Olson AK, Shih R, Bansal N, Lal A, Gambetta K, Hsu D, Cripe L, Villa C, Nandi D. Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance. J Neuromuscul Dis. 2025 Mar; 12(2):173-182.
-
Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Guridi M, Murphy AP, Reid C, Wandel C, Asher DR, Darton E, Mason S, Potter RA, Singh T, Zhang W, Fontoura P, Elkins JS, Rodino-Klapac LR. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025 Jan; 31(1):332-341.
-
O'Connell N, van der Valk P, Le Quellec S, Gomez E, Monahan PE, Crary SE, Coppens M, Lemons R, Castaman G, Klamroth R, Symington E, Quon DV, Kampmann P. Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B. J Thromb Haemost. 2025 Jan; 23(1):73-84.
-
Veerapandiyan A, Duvuru R. Transforming care for spinal muscular atrophy: A critical look at treatment paradigms. Mol Ther. 2024 Aug 07; 32(8):2435-2436.
-
Leavitt AD, Konkle BA, Stine KC, Visweshwar N, Harrington TJ, Giermasz A, Arkin S, Fang A, Plonski F, Yver A, Ganne F, Agathon D, Resa MLA, Tseng LJ, Di Russo G, Cockroft BM, Cao L, Rupon J. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta?study. Blood. 2024 02 29; 143(9):796-806.
-
Zaidman CM, Goedeker NL, Aqul AA, Butterfield RJ, Connolly AM, Crystal RG, Godwin KE, Hor KN, Mathews KD, Proud CM, Kula Smyth E, Veerapandiyan A, Watkins PB, Mendell JR. Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2024; 11(3):687-699.
-
Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023 02 23; 388(8):706-718.
-
Ozes B, Myers M, Moss K, Mckinney J, Ridgley A, Chen L, Bai S, Abrams CK, Freidin MM, Mendell JR, Sahenk Z. AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1. Gene Ther. 2022 04; 29(3-4):127-137.
-
Khaled M, Moustafa AS, El-Khazragy N, Ahmed MI, Abd Elkhalek MA, El Salahy EM. CRISPR/Cas9 mediated knock-out of VPREB1 gene induces a cytotoxic effect in myeloma cells. PLoS One. 2021; 16(1):e0245349.
-
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
-
Liu Z, Anderson JD, Deng L, Mackay S, Bailey J, Kersh L, Rowe SM, Guimbellot JS. Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis. Genes (Basel). 2020 05 29; 11(6).
-
Feldman AG, Parsons JA, Dutmer CM, Veerapandiyan A, Hafberg E, Maloney N, Mack CL. Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1. J Pediatr. 2020 10; 225:252-258.e1.
-
Hay CE, Ewing LE, Hambuchen MD, Zintner SM, Small JC, Bolden CT, Fantegrossi WE, Margaritis P, Owens SM, Peterson EC. The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse. J Pharmacol Exp Ther. 2020 07; 374(1):16-23.
-
Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. Ann Pharmacother. 2020 10; 54(10):1001-1009.
-
Samanta D. Changing Landscape of Dravet Syndrome Management: An Overview. Neuropediatrics. 2020 04; 51(2):135-145.
-
Conrad SJ, Liu J. Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes. Methods Mol Biol. 2019; 1937:189-209.
-
D'Mello S, Atluri K, Geary SM, Hong L, Elangovan S, Salem AK. Bone Regeneration Using Gene-Activated Matrices. AAPS J. 2017 01; 19(1):43-53.
-
Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother. 2016 06; 39(5):191-201.
-
Homberg JR, Kyzar EJ, Scattoni ML, Norton WH, Pittman J, Gaikwad S, Nguyen M, Poudel MK, Ullmann JF, Diamond DM, Kaluyeva AA, Parker MO, Brown RE, Song C, Gainetdinov RR, Gottesman II, Kalueff AV. Genetic and environmental modulation of neurodevelopmental disorders: Translational insights from labs to beds. Brain Res Bull. 2016 07; 125:79-91.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|